GenSpera is Safety-Testing Thapsigargin to Target Cancer Cells

GenSpera’s first drug, G-202, targets PSMA Enzyme, found on the walls of the blood vessels that feed cancer tumors, regardless of the type of cancer.   G-202 is currently in phase 1 safety trials at the University of Wisconsin Carbone Cancer Center (Madison, Wisconsin),  the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, and the Cancer Therapy & Research Center at the University of Texas Health Science Center of San Antonio, at San Antonio, Texas.

At the completion of this multi-center trial, GenSpera expects to move on to Phase 2 trials possibly in prostate, stomach and other cancers, all with the same drug, G-202.

In the case of GenSpera’s second drug, G-115, its target is PSA, an enzyme found only in prostate cancer tumors.

See:  http://www.genspera.com/

Print Friendly, PDF & Email